Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$38.71+0.10 (+0.26%)
Close on Nov 17, 2026Market cap $27.96BP/E –Yield –
Roivant Sciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Roivant Sciences's price to sales ratio was 444.3× on Sep 30, 2025, against 235.5× a year earlier. Over the last 4 years it ranged from 41.7× to 444.3×, with a median of 135.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Sep 30, 2025 | 444.3× | +210.1 |
| 2024 | Dec 31, 2024 | 234.2× | +105.1 |
| 2023 | Dec 29, 2023 | 129.0× | +17.4 |
| 2022 | Dec 30, 2022 | 111.6× | −50.3 |
| 2021 | Dec 31, 2021 | 162.0× | – |
See a number that looks wrong?